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The aim of the study is identification of correlations
between the serum concentrations of iron and the risk
of breast and/or ovarian cancer among female BRCA1
mutations carriers.
The subjects selected for the trial were Polish women,
positive for at least one of three founder mutations in
BRCA1 gene dominating in Poland (5382insC, C61G,
4153delA). Persons with detected tumor were considered
as cases and the others were considered as controls. One
case and two controls were paired regarding many criteria
(e.g. age, family cancer history, cigarettes smoking) to
achieve the maximum of similarity between them.
The proportion of cases and control in the first quartile
was taken as a reference to calculate the odds ratio, confi-
dence interval and p-value of the multivariate conditional
logistic regression.
The iron was quantitatively measured by ICP-MS
(Inductively Coupled Plasma Mass Spectrometry),
(model Elan DRC-e 6100 th, PerkinElmer).
This study shows that concentration levels of iron in
blood serum are a strong factors associated with an
additionally increased risk of breast and ovarian cancer
among BRCA1 mutation carriers.
For iron concentration, all quartiles above the first one
had a decreased risk of breast or ovarian cancer. The
results are shown in Table 1.
Similarly, high ratios of iron to selenium were signifi-
cantly associated with disease protection which is shown
in Table 2.
Published: 20 April 2012
doi:10.1186/1897-4287-10-S3-A21
Cite this article as: Sukiennicki et al.: Serum concentration of iron as
predictor of cancer risk among BRCA1 mutation carriers. Hereditary
Cancer in Clinical Practice 2012 10(Suppl 3):A21.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit * Correspondence: gsukiennicki@wp.pl
Read-Gene SA and Pomeranian Medical University, Szczecin, Poland
Table 1 Iron concentration in each quartile
Fe (µg/l) Cases (n=99) Controls (n=198) OR p-value
370,95 – 977,64[ 34 (34,3%) 40 (20,2%) 1,000 -
[977,64 – 1262,78[ 24 (24,2 %) 50 (25,3%) 0,565 0.01229
[1262,78 – 1571,11[ 24 (24,2%) 50 (25,3%) 0,565 0.13885
[1571,11 – 4756,15 17 (17,17%) 58 (29,3%) 0,345 0.00823
Table 2 Ratios between iron and selenium
Fe/Se Cases (n=99) Controls (n=198) OR p-value
0.86-12.78 34 (34,3%) 40 (20,2%) 1,000 -
12.78-15.84 25 (25,3%) 49 (24,7%) 0,600 0.094608
15.84-19.72 18 (18,2%) 56 (28,3%) 0,378 0.006507
19.72-59.3 22 (22,2%) 53 (26,8%) 0,488 0.007813
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